Janssen says culture media HyClone Laboratories makes for Celltrion infringe on a US patent covering broths used in the manufacture of Remicade (infliximab).
Adaptimmune has entered into a new 10-year development and supply agreement for use of thermos Fisher’s Dynabeads CD3/CD28 CTS T-cell isolation, activation and expansion technology.
DNA vaccines are safer and quicker to produce than egg or cell-based products, says VGXI which manufactured material for a recently approved first-in-man study of a Zika vaccine.
As part of a cost-savings restructure, Epirus is selling the assets from its $14m acquisition of Bioceros last September to its biosimilars partner Polpharma.
ProteoNic Biotechnology has licensed a vector gene delivery system to Horizon Discovery in a deal it hopes will attract firms looking to eliminate methionine sulphoximine from CHO cell selection processes.
Differentiated technologies buoyed by the recent $600m conjugation deal with Roche is driving Catalent’s biologics business, the firm told Biopharma-Reporter at BIO.
Single-use technology is driving a new era in vaccine development says PnuVax which has acquired IP from GE Healthcare to produce an inactivated yellow fever vaccine.
Increased demand for gene therapy services will drive further investment in Lonza's capabilities, the firm says as it inks a strategic deal with Bluebird.
India’s first off-the-shelf cell therapy product, StemCells Inc plummets on Phase II trial termination, and Accellta looks to 3D printing. Welcome to Biopharma-Reporter’s stem cell round-up…
The UK Cell and Gene Therapy Catapult (CGT) will test a “scaffold” technology its Australian developers say could make T-cell production more efficient.
Evercyte has teamed up with VTU Technology to develop cell culture media free from animal derived products, which the firm says is now essential for biomanufacturers.
Octapharma has withdrawn one lot of its immune deficiency treatment Octagam after receiving reports of reports of allergic skin reactions in patients treated with the product.
Brexit would create regulatory uncertainty, delay the launch of biosimilars and prevent NHS cost savings according to the newly founded British Biosimilars Association (BBA).
Cell therapy and radiotracer production has halted at two facilities operated by the US National Institutes of Health (NIH) after consultants raised concerns about quality and manufacturing standards.
Single-use is the future but stainless steel bioreactors will always play a role in drug production says an expert, who thinks firms could do worse than consult a CMO before deciding in which technology to invest.
Fully understanding a molecule’s mode-of-action (MOA) will be essential as industry begins developing the third generation of biosimilar products, according to Formycon.
Microbial expression systems are cheaper and more efficient than mammalian cell cultures says BioSilta which has acquired the rights to an E. coli based platform.
Eppendorf will tackle the challenges of scaling-up human induced pluripotent stem cells (hiPSCs) as part of a Horizon 2020 project to develop cell-based heart therapies.
Cell therapy firms must invest in engineering and learn from biopharma according to the US Government, which says high cost of regenerative treatments is slowing uptake.
Bristol-Myers Squibb has announced plans to set up a biomanufacturing process laboratory in collaboration with Ireland's National Institute of Bioprocessing Research and Training (NIBRT).
Know-how underpinning the tech astronauts use to detect infections in space could streamline cell therapy manufacturing according to new GE Healthcare partner LeukoDx.
Plasticell has teamed up with encapsulation and screening tech firm Sphere Fluidics to develop genetic modification technology for cell therapy production.
LeukoDx will develop a cell characterization system for GE Healthcare in a deal designed to bolster the latter’s cell therapy manufacturing technology offering.
TxCell is working on new ways of delivering its Crohn's disease therapy Ovasave that will replace the somewhat unusual method it is using in clinical trials.
Lonza has launched a reformulated CHO media that it says supports the growth of higher density cultures and is easier to filter than currently available products.
An influenza vaccine produced in tobacco plants could make a big impact in the market if it reaches the market in the US in time for the 2018-19 flu season, says a market analyst.
A bone marrow therapy available to workers cleaning up after the Fukushima nuclear plant meltdown relies on a novel bioreactor tech that cultures cells in 3D.
